How a struggling biotech company became a university ‘spin-in’

Nature, Published online: 10 September 2024; doi:10.1038/d41586-024-02627-8

Despite meeting a clinical and societal need for snakebite antivenom development, VenomAb folded after four years, propelling co-founder Andreas Laustsen-Kiel to a role that combines entrepreneurship and academia.